SolasCure has been named the winner of the biotech category at the EIT Health Catapult finals in Stockholm.
The medical use of Aurase Wound Gel is being developed with the aim of accelerating wound cleaning. Our proprietary technology leverages biomimicry and evidence-based medicine to develop treatments for patients with chronic wounds in all settings: hospitals, nursing homes, or home care.
EIT Health Catapult is a unique competition and training programme that showcases biotech, medtech and digital health start-ups to leading experts and investors across Europe. The programme recognises the very best business concepts, fast-tracking start-ups to become part of the EIT Health Community of world-leading companies. EIT Health is supported by the European Institute of Innovation & Technology (EIT), a body of the European Union.
This prestigious international recognition follows the recent news that SolasCure’s preclinical research, performed on behalf of the company by the University of Miami, was named the Best Laboratory Science abstract at the Symposium on Advanced Wound Care (SAWC), the premier global wound healing conference in the world.
Find out the latest news from SolasCure: www.solascure.com/news